Henry Schein(US:HSIC)2025-05-05 11:05Financial Performance - The company reported total sales of $3.168 billion in Q1 2025, a decrease of 0.1% compared to $3.172 billion in Q1 2024 [17, 56] - Non-GAAP diluted EPS increased by 4.5% from $1.10 in Q1 2024 to $1.15 in Q1 2025 [14, 56] - Adjusted EBITDA grew by 1.7% from $255 million in Q1 2024 to $259 million in Q1 2025 [14, 17, 59] - The company is maintaining its 2025 guidance, including Non-GAAP EPS of $4.80 to $4.94 and total sales growth of +2% to +4% [10, 50] Segment Performance - Global Distribution and Value-Added Services Group sales grew by 1.5% excluding PPE and COVID test kits [14, 24] - Global Specialty Products Group sales increased by 4.3% due to gains in implants and biomaterials [14, 27, 28] - Global Technology Group sales grew by 3.4%, driven by practice management systems [14, 33, 35] Strategic Initiatives - The company is advancing its BOLD+1 Strategic Plan, expecting high-growth, high-margin businesses to contribute over 50% of total operating income by 2027, plus over 10% from corporate brand products [10] - The company invested $31 million in capital expenditures and $51 million in acquisitions in Q1 2025 [41] - $161 million was used for share repurchases in Q1, with $718 million remaining under the share repurchase authorization [41]